Last reviewed · How we verify
NCT07269106
Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery
Phase 4 trial testing Anrikefon in Ophthalmic Surgery in 204 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Zhongshan Ophthalmic Center, Sun Yat-sen University |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 204 |
| Start date | 22 January 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Anrikefon — full drug profile →
- Nalbuphine — full drug profile →
Conditions studied
- Ophthalmic Surgery — all drugs for Ophthalmic Surgery →
- Postoperative Pain Management — all drugs for Postoperative Pain Management →
- Opioid Analgesia — all drugs for Opioid Analgesia →
Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Who can join
Adults 18 to 70, any sex, with Ophthalmic Surgery or Postoperative Pain Management. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if Anrikefon works as well as nalbuphine to control postoperative pain in adults undergoing ophthalmic surgery under general anesthesia. It will also learn about the safety and recovery outcomes of using Anrikefon. The main questions it aims to answer are: * Does Anrikefon provide pain relief that is not inferior to nalbuphine after ophthalmic surgery? * Does Anrikefon cause fewer central side effects, such as sedation or dizziness, compared with nalbuphine? * Does Anrikefon help patients recover and get discharged faster after day-surgery procedures? Researchers will compare Anrikefon to nalbuphine to see if Anrikefon can offer effective and safer perioperative analgesia for ophthalmic day-surgery patients. Participants will: * Receive either an intravenous dose of Anrikefon or nalbuphine during surgery. * Be monitored for pain scores, side effects, and recovery parameters after surgery. * Complete follow-up assessments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07269106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anrikefon
Trials testing the same drug.
- NCT07380113 — Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP · Phase 4 · not yet recruiting
- NCT07514637 — Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.I · Phase 2 · recruiting
Other Zhongshan Ophthalmic Center, Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07524725 — Effect of Behavioral Intervention (Baduanjin Alone or Laughter Exercise Plus Artificial Tears) Versus Artificial Tear on · NA · not yet recruiting
- NCT07096622 — Efficacy of Visual and Perceptual Training on Visual Function for Operative Congenital Ectopia Lentis Children · NA · not yet recruiting
- NCT06098677 — Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects · NA · not yet recruiting
- NCT07512115 — The Impact of 'A Miss Is as Good as a Mile': Is Compensation Necessary for Minimal Ocular Deviation in Myopic Laser Surg · NA · not yet recruiting
- NCT07512089 — Comparison of PRESBYOND Laser Blended Vision and Conventional Monovision LASIK in Individuals With Presbyopia: A Randomi · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07269106 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongshan Ophthalmic Center, Sun Yat-sen University
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07269106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing